Eimear E Kenny, PhD
- DIRECTOR, INSTITUTE FOR GENOMIC HEALTH
- PROFESSOR | Medicine, General Internal Medicine
- PROFESSOR | Genetics and Genomic Sciences
Research Topics:
Genetics, Genomics
Dr. Eimear Kenny, PhD, is Founding Director of the Institute for Genomic Health, and Associate Professor of Medicine and Genetics at Mount Sinai. She lead research at the interface of genomics, medicine, and computer science. Her research spans a number of different fields, including population and statistical genetics; computational and machine-learning approaches for genomics; biobank- and cohort-based research on monogenic disorders and common diseases; polygenic risk for human diseases and precision medicine. Her goal is to lead a new paradigms for genomic research and to enable genomic medicine on a global scale. She is Principal Investigator in six large international programs focused on genomic research, medicine and health, and is in the top 20 NIH-funded genomics researchers in the US. She is a scientific advisor to many genomic and genomic medicine initiatives in government, non-profit and industry arenas. She has published over 90 papers in leading journals like Science, Nature, Nature Genetics, NEJM, with over 13,000 citations, and her work has been featured by many media outlets including the New York Times.
She has a BA in Biochemistry from Trinity College Dublin, a PhD in computational genomics from Rockefeller University, and did her postdoctoral training in population genetics at Stanford University.
Multi-Disciplinary Training Area
Genetics and Data Science [GDS]Education
BSc, Trinity College Dublin
MSc, University of Leeds
PhD, Rockefeller University
Post-doc, Stanford University
Research Interests:
Dr. Kenny is Founding Director of the Center for Genomic Health (CGH). She leads a
multidisciplinary team of geneticists, computer scientists, clinicians, and
other medical professionals, working on problems at the interface of
computational genomics and medicine. Her goal is to bring state-of-the-art
genomic technology and data science to improve clinical care, particularly in diverse
and medically underserved populations. Current activities in CGH include
genomic discovery in biobanks and disease cohorts using databases of hundreds
of thousands of human genomes; a large clinical trial to examine how complex
genomic information is communicated in health systems; and a program to offer
genomic screening in clinical care to enable early detection and prevention of
diseases, such as breast cancer, diabetes and heart disease. She is scientific advisor to multiple genomic
medicine initiatives in non-profit, government and industry arenas.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Kenny did not report having any of the following types of financial relationships with industry during 2020 and/or 2021: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.